Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine Substitution

• Published in: Metabolites Vol. 14; no. 10; p. 565
• Main Authors: Berta, Eszter, Halmi, Sándor, Molnár, István, Hutkai, Dávid, Csiha, Sára, Bhattoa, Harjit Pal, Lőrincz, Hajnalka, Somodi, Sándor, Katkó, Mónika, Harangi, Mariann, Paragh, György, Nagy, Endre V, Bodor, Miklós
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.10.2024; MDPI
• Subjects: Adipose tissue; Age; Arteriosclerosis; Atherosclerosis; Blood vessels; Body fat; C-reactive protein; Cardiovascular disease; Cholesterol; Diabetes; Enzyme-linked immunosorbent assay; FGF21; fibroblast growth factor 21; Fibroblasts; Glucose; Glucose metabolism; Growth factors; Hashimoto’s thyroiditis; High density lipoprotein; Hormones; hyperlipidemia; Hypothalamus; Hypothyroidism; Kinases; levothyroxine; Lipid metabolism; Lipoproteins; Liver diseases; Metabolic disorders; Obesity; Regression analysis; Statistical analysis; thyroid; Thyroid diseases; Thyroid gland; Thyroid hormones; Thyroiditis; Thyroxine; Variables; Weight control; White people; United States > US; Germany; fibroblast growth factor 21; hyperlipidemia; levothyroxine; thyroid; hypothyroidism; Hashimoto’s thyroiditis; FGF21
• ISSN: 2218-1989; 2218-1989
• DOI: 10.3390/metabo14100565

Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT). Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.